Kyowa Kirin 将来の成長

Future 基準チェック /16

Kyowa Kirin利益と収益がそれぞれ年間6.1%と3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に8.7% 6.5%なると予測されています。

主要情報

6.1%

収益成長率

6.5%

EPS成長率

Pharmaceuticals 収益成長	11.9%
収益成長率	3.0%
将来の株主資本利益率	8.7%
アナリストカバレッジ	Good
最終更新日	31 Oct 2024

今後の成長に関する最新情報

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Recent updates

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Oct 22

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

業績と収益の成長予測

TSE:4151 - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	521,355	82,010	76,287	101,748	11
12/31/2025	498,283	74,393	68,222	94,181	12
12/31/2024	491,762	70,087	-48,626	53,052	12
9/30/2024	498,978	83,535	46,087	100,857	N/A
6/30/2024	475,998	97,319	49,961	102,058	N/A
3/31/2024	454,267	83,060	72,937	105,333	N/A
12/31/2023	442,233	81,188	82,699	115,551	N/A
9/30/2023	420,649	57,915	61,057	97,415	N/A
6/30/2023	412,309	40,202	50,976	86,560	N/A
3/31/2023	404,155	50,295	36,838	69,288	N/A
12/31/2022	398,371	53,573	20,006	48,672	N/A
9/30/2022	382,052	68,651	23,914	40,905	N/A
6/30/2022	372,496	62,292	64,227	85,957	N/A
3/31/2022	358,882	55,464	60,509	80,951	N/A
12/31/2021	352,246	52,347	66,782	86,548	N/A
9/30/2021	338,317	42,446	63,711	88,827	N/A
6/30/2021	325,554	44,301	17,545	41,994	N/A
3/31/2021	322,174	46,106	17,073	53,289	N/A
12/31/2020	318,352	47,027	4,275	39,502	N/A
9/30/2020	314,367	48,255	17,193	46,918	N/A
6/30/2020	312,223	46,819	23,579	54,415	N/A
3/31/2020	307,278	42,212	25,441	45,066	N/A
12/31/2019	305,820	37,674	32,398	53,655	N/A
9/30/2019	374,267	38,519	18,271	48,406	N/A
6/30/2019	325,827	38,796	25,458	46,189	N/A
3/31/2019	337,645	41,713	24,079	45,912	N/A
12/31/2018	346,531	54,414	36,039	56,181	N/A
9/30/2018	292,662	65,953	N/A	N/A	N/A
6/30/2018	349,815	63,500	N/A	63,527	N/A
3/31/2018	347,166	56,420	N/A	N/A	N/A
12/31/2017	353,380	42,899	N/A	64,902	N/A
9/30/2017	343,697	21,949	N/A	N/A	N/A
6/30/2017	344,648	21,576	N/A	70,039	N/A
3/31/2017	345,485	19,754	N/A	N/A	N/A
12/31/2016	343,019	18,669	N/A	65,752	N/A
9/30/2016	349,134	20,199	N/A	N/A	N/A
6/30/2016	359,535	31,014	N/A	70,472	N/A
3/31/2016	363,187	32,566	N/A	N/A	N/A
12/31/2015	364,316	29,774	N/A	66,526	N/A
9/30/2015	367,453	29,906	N/A	N/A	N/A
6/30/2015	350,384	16,236	N/A	42,854	N/A
3/31/2015	336,965	14,173	N/A	N/A	N/A
12/31/2014	333,446	15,898	N/A	19,377	N/A
9/30/2014	327,444	18,791	N/A	N/A	N/A
6/30/2014	332,803	21,585	N/A	35,661	N/A
3/31/2014	340,090	26,010	N/A	N/A	N/A
12/31/2013	340,611	30,078	N/A	56,884	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 4151の予測収益成長率 (年間6.1% ) は貯蓄率 ( 0.3% ) を上回っています。

収益対市場: 4151の収益 ( 6.1% ) JP市場 ( 8.9% ) よりも低い成長が予測されています。

高成長収益: 4151の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 4151の収益 ( 3% ) JP市場 ( 4.2% ) よりも低い成長が予測されています。

高い収益成長: 4151の収益 ( 3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 4151の自己資本利益率は、3年後には低くなると予測されています ( 8.7 %)。

Kyowa Kirin 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Investor sentiment deteriorates as stock falls 17%

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop